Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Retained Earnings (2017 - 2025)

Historic Retained Earnings for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to -$437.3 million.

  • Innate Pharma's Retained Earnings fell 2054.94% to -$437.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$437.3 million, marking a year-over-year decrease of 2054.94%. This contributed to the annual value of $29223.1 for FY2024, which is 9454.23% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Retained Earnings is -$437.3 million, which was down 2054.94% from $28852.1 recorded in Q4 2024.
  • Innate Pharma's Retained Earnings' 5-year high stood at $835582.5 during Q4 2022, with a 5-year trough of -$437.3 million in Q2 2025.
  • Over the past 5 years, Innate Pharma's median Retained Earnings value was -$265.5 million (recorded in 2021), while the average stood at -$190.4 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first surged by 9982.95% in 2021, then plummeted by 9458.27% in 2024.
  • Quarter analysis of 5 years shows Innate Pharma's Retained Earnings stood at $521650.8 in 2021, then skyrocketed by 60.18% to $835582.5 in 2022, then crashed by 36.26% to $532590.3 in 2023, then tumbled by 94.58% to $28852.1 in 2024, then crashed by 1515930.11% to -$437.3 million in 2025.
  • Its Retained Earnings was -$437.3 million in Q2 2025, compared to $28852.1 in Q4 2024 and -$362.8 million in Q2 2024.